Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mutational resistance to 4-quinolone antibacterial agents.

Literature DB >> 6237904

Mutational resistance to 4-quinolone antibacterial agents.

Abstract

The activity of ten 4-quinolone drugs was tested against five Escherichia coli mutants. Mutational resistance was found to reduce the activity of all ten drugs, indicating that they display biochemical cross-resistance with each other. However, ciprofloxacin and, to a lesser extent, ofloxacin and norfloxacin were so highly active that the most resistance exhibited by any mutant fell well within the serum drug concentration ranges attainable in humans. Hence, clinical cross-resistance in Escherichia coli at least, need not necessarily apply to such highly active 4-quinolone antibacterial agents.

Entities: Chemical Species

Mesh：

Substances：

Year: 1984 PMID： 6237904 DOI： 10.1007/bf01977492

Source DB: PubMed Journal: Eur J Clin Microbiol ISSN： 0722-2211 Impact factor: 3.267

4 in total

1. The effect of R-factor plasmids on host-cell responses to nalidixic acid I. Increased susceptibility of nalidixic acid-sensitive hosts.

Authors: G C Crumplin; J T Smith
Journal: J Antimicrob Chemother Date: 1981-04 Impact factor: 5.790

2. Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids.

Authors: S Inoue; T Ohue; J Yamagishi; S Nakamura; M Shimizu
Journal: Antimicrob Agents Chemother Date: 1978-08 Impact factor: 5.191

3. Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

Authors: M W Hane; T H Wood
Journal: J Bacteriol Date: 1969-07 Impact factor: 3.490

4. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

Authors: M Gellert; K Mizuuchi; M H O'Dea; T Itoh; J I Tomizawa
Journal: Proc Natl Acad Sci U S A Date: 1977-11 Impact factor: 11.205

4 in total

36 in total

1. Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections.

Authors: P Rattanaumpawan; P Tolomeo; W B Bilker; N O Fishman; E Lautenbach
Journal: J Hosp Infect Date: 2010-12 Impact factor: 3.926

2. Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers.

Authors: J S Wolfson; D C Hooper; E Y Ng; K S Souza; G L McHugh; M N Swartz
Journal: Antimicrob Agents Chemother Date: 1987-11 Impact factor: 5.191

7. Comparative therapeutic activities of ciprofloxacin, amoxicillin, ceftriaxone and co-trimoxazole in a new model of experimental infection with Escherichia coli.

Authors: H Hof; A Christen; J Hacker
Journal: Infection Date: 1986 Jul-Aug Impact factor: 3.553

Mutational resistance to 4-quinolone antibacterial agents.

1. The effect of R-factor plasmids on host-cell responses to nalidixic acid I. Increased susceptibility of nalidixic acid-sensitive hosts.

2. Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids.

3. Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies.

4. Nalidixic acid resistance: a second genetic character involved in DNA gyrase activity.

1. Risk factors for fluoroquinolone resistance in Gram-negative bacilli causing healthcare-acquired urinary tract infections.

2. Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers.

3. Functional relationship between bacterial cell density and the efficacy of antibiotics.

Review 4. Genotypic approach to the study of bacterial resistance to antibiotics.

5. In vitro activities of 4-quinolones against the fish pathogen Aeromonas salmonicida.

6. Antibacterial and plasmid curing activity of lomefloxacin in vitro.

7. Comparative therapeutic activities of ciprofloxacin, amoxicillin, ceftriaxone and co-trimoxazole in a new model of experimental infection with Escherichia coli.

8. Isolation and characterization of norfloxacin-resistant mutants of Escherichia coli K-12.

Review 9. Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Review 10. Quinolone mode of action--new aspects.